• Skip to primary navigation
  • Skip to content
  • Skip to footer
Gynesonics

Gynesonics

Advancing technology. Improving women's lives.

  • Our Company
    • About Us
    • Careers
    • Compliance
  • Our People
    • Management
    • Board of Directors
    • Investors
  • Our Technology
    • The Sonata System
    • Indications and Safety
    • Instructions for Use
    • Request for Medical or Scientific Information
  • Our News
    • Press Releases
    • Publications
  • Contact Us

Press Releases

Jan 10, 2019

Gynesonics Announces Publication of Final SONATA IDE Pivotal Trial Results in the Journal, Obstetrics And Gynecology

Robust Outcomes Support the Potential of the Sonata System as a  First-Line Treatment for Symptomatic Uterine Fibroids Redwood City, CA – January 10, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas) today announced the publication of the SONATA IDE […]

Jan 3, 2019

Gynesonics Announces $75 Million Equity Financing

Equity Round led by Bain Capital Life Sciences Redwood City, CA – January 3, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata System and other advanced, incision-free solutions for the treatment of uterine conditions, today announced that it has completed a $75 million equity financing. The financing was led by […]

Nov 12, 2018

Gynesonics Technology to be Featured in Presentations at 2018 AAGL Global Congress

Impressive 12-Month Patient Outcomes from SONATA Pivotal IDE Trial Being Highlighted Redwood City, CA – Nov 12, 2018 – Gynesonics, a women’s healthcare company focused on the development of advanced minimally invasive solutions for the treatment of uterine conditions, today announced that its Sonata® System for transcervical treatment of uterine fibroids will be featured in […]

Aug 22, 2018

Gynesonics Receives FDA Clearance to Market Sonata® System

Advanced technology offers potential to become a new standard of care for fibroid treatment Redwood City, CA – August 22, 2018 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to […]

Jan 9, 2018

Gynesonics Announces Results from Pivotal IDE Trial for Incision Free Treatment of Uterine Fibroids

Results highlight robust Sonata System design and its potential to become a standard of care for fibroid treatment Redwood City, CA – January 9, 2018 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the results from their pivotal IDE trial for the Sonata® […]

Dec 21, 2017

Gynesonics Announces Submission of FDA 510K for Incision-Free Treatment of Symptomatic Uterine Fibroids

Novel uterus-preserving Sonata System is first incision-free treatment to address majority of fibroids transcervically Redwood City, CA – December 21, 2017 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for uterine fibroids, today announced its submission to the FDA of its 510(k) Premarket Notification for the Sonata® System, a […]

Mar 30, 2017

Gynesonics names James Sparks Vice President of Manufacturing

Respected Leader in Medical Device Manufacturing and Engineering Management Redwood City, CA – March 30, 2017 – Gynesonics, a women’s healthcare company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of symptomatic uterine fibroids, today announced that medical device executive James Sparks has been named Vice President […]

Nov 10, 2016

Data from Sonata Technology Platform Featured in Presentations at AAGL Global Congress in Orlando

First Health Economic Outcomes Research with Sonata Treatment to be Presented Redwood City, CA – Nov 10, 2016 – Gynesonics, a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions, today announced that its Sonata® System technology platform for transcervical incision-free treatment of uterine fibroids will be […]

Oct 19, 2016

Sonata Technology Platform Featured in Presentations at Upcoming Congress of the German Society of Obstetrics and Gynecology (DGGG)

Increasing Body of Evidence Further Demonstrates Compelling Outcomes Redwood City, CA – October 19, 2016 – Gynesonics, a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions, today announced that its Sonata® System technology platform for transcervical incision-free treatment of uterine fibroids will be featured in three […]

Oct 18, 2016

Gynesonics Announces Early Completion of Enrollment in the SONATA FDA Clinical Trial for Incision Free Treatment of Symptomatic Uterine Fibroids

Company Expects to Submit Trial Results to FDA in Fourth Quarter of 2017 Redwood City, CA – October 18, 2016 – Gynesonics, a women’s healthcare company focused on the development of advanced incision-free solutions for treatment of benign uterine conditions, today announced the completion of enrollment in the SONATA Investigational Device Exemption (IDE) clinical trial, […]

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next »

Footer

  • Privacy Policy
  • Terms of Use
  • Patents
  • Safety Information

© Copyright 2022 Gynesonics · All Rights Reserved · WS 05198 Rev. J

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Gynesonics
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.